Optimisation of botulinum toxin type a treatment for the management of Raynaud’s phenomenon using a dorsal approach: a prospective case series

[1] Uppal L(2014)A prospective study of the use of botulinum toxin injections in the treatment of Raynaud’s syndrome associated with systemic sclerosis J Hand Surg Eur Vol 39 876-880

[2] Dhaliwal K(1990)Prevalence of symptoms of Raynaud’s phenomenon in general practice BMJ 301 590-592

[3] Butler P(1988)An epidemiological survey of Raynaud’s phenomenon Eur J Vasc Surg 2 167-170

[4] Silman A(2003)Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with systemic sclerosis-associated lung fibrosis and the raynaud phenomenon Ann Intern Med 139 871-873

[5] Holligan S(2009)MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized, controlled trial Arthritis Rheum 60 870-877

[6] Brennan P(2010)Advances in the treatment of Raynaud’s phenomenon Vasc Health Risk Manag 6 167-177

[7] Maddison P(2015)Management of Raynaud’s Phenomenon and digital ulcers Curr Treat Opt Rheumatol 1 68-81

[8] De Trafford J(2013)Current medical and surgical management of Raynaud’s syndrome J Vasc Surg 57 1710-1716

[9] Lafferty K(2004)Botulinum toxin in the treatment of Raynaud’s phenomenon: a pilot study Eur J Clin Investig 34 312-313

[10] Potter C(2009)Botox therapy for ischemic digits PRS 124 191-201

[1] Uppal L(2014)A prospective study of the use of botulinum toxin injections in the treatment of Raynaud’s syndrome associated with systemic sclerosis J Hand Surg Eur Vol 39 876-880

[2] Dhaliwal K(1990)Prevalence of symptoms of Raynaud’s phenomenon in general practice BMJ 301 590-592

[3] Butler P(1988)An epidemiological survey of Raynaud’s phenomenon Eur J Vasc Surg 2 167-170

[4] Silman A(2003)Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with systemic sclerosis-associated lung fibrosis and the raynaud phenomenon Ann Intern Med 139 871-873

[5] Holligan S(2009)MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized, controlled trial Arthritis Rheum 60 870-877

[6] Brennan P(2010)Advances in the treatment of Raynaud’s phenomenon Vasc Health Risk Manag 6 167-177

[7] Maddison P(2015)Management of Raynaud’s Phenomenon and digital ulcers Curr Treat Opt Rheumatol 1 68-81

[8] De Trafford J(2013)Current medical and surgical management of Raynaud’s syndrome J Vasc Surg 57 1710-1716

[9] Lafferty K(2004)Botulinum toxin in the treatment of Raynaud’s phenomenon: a pilot study Eur J Clin Investig 34 312-313

[10] Potter C(2009)Botox therapy for ischemic digits PRS 124 191-201